Interview, Fireside Chat
Mastering Your Data with Sajith Wickramasekara
- Scientists are expected to unravel biological mysteries and dramatically accelerate the ability to solve human health problems over the course of this century.
- Biotechnology tools are projected to evolve from blunt instruments to precise "scalpels," reshaping the world through enhanced harnessing of biological power.
- The biopharmaceutical pipeline is expected to remain dominated by biologics and advanced modalities, a trend that represents a significant shift from 2012 predictions.
- Large pharmaceutical companies are increasingly choosing to develop proprietary software in-house due to the recognized complexity of biological data models and available resources.
- Industry-wide risks are expected to include numerous failures, though the active pursuit of risk is viewed as a positive indicator for optimism.
- Benchling plans to spend approximately $100 million annually on R&D, with roughly 40 of its 800 team members dedicated to research, to maintain alignment with cutting-edge science.
- New bio-AI models are predicted to generate a tenfold increase in high-quality therapeutic molecule ideas and significantly reduce the toil involved in moving drugs from idea to animal studies, human trials, process development, and manufacturing.
- The organization of data foundations is identified as a multi-year endeavor for large enterprises like Sanofi, requiring top-level leadership and organizational alignment to overcome the prevalence of unstructured or "dark" data.
- Benchling intends to expand its service scope from research into development and potential manufacturing segments over the next 12 years to help companies speed up drug market entry.
- The company plans to shift its strategy from a modular "Lego brick" approach to providing fully finished products and industry perspectives for mature customers.
- Benchling aims to improve empathy, change management, and unified customer experiences by hiring additional specialists.
- High-value opportunities exist in capturing in vivo data for advanced modalities such as cell and gene therapies, which are currently underappreciated in the industry.